What Is mOS? Median Overall Survival Explained for Biotech Investors

mOS stands for median overall survival. It is one of the most important endpoints in oncology clinical trials.

Median overall survival is the time point at which half of the patients in a study group have died and half are still alive. If a cancer trial reports a median overall survival of 18 months, that means 50% of patients in that group were alive at 18 months and 50% had died.

mOS is not the same as average survival. It is the median point in the survival distribution.

Simple example

Imagine a trial with 100 patients in the treatment arm. If the 50th death happens 20 months after randomization, the median overall survival is approximately 20 months. If fewer than 50 patients have died by the time of analysis, the median overall survival has not yet been reached. This is often reported as “mOS not reached” or “median OS not reached.”

Read more: What Does “Median Not Reached” Mean?

Why mOS matters

In cancer trials, overall survival is one of the clearest endpoints because it asks the most important question: did patients live longer?

For biotech investors, mOS can move stocks dramatically. If a new cancer drug improves mOS versus the control arm, the market may view the drug as clinically meaningful and commercially valuable.

However, mOS should not be interpreted alone. Investors should also look at hazard ratio, p-value, confidence interval, Kaplan-Meier curves, censoring, trial maturity, control-arm performance, safety, patient population, treatment crossover and post-progression therapies.

Read more: Hazard Ratio Explained for Biotech Investors

mOS vs OS

Overall survival, or OS, is the general endpoint. Median overall survival, or mOS, is one way of summarizing OS data. A trial can report OS as median survival, hazard ratio for death, one-year survival, two-year survival or a full Kaplan-Meier curve.

mOS is easy to understand, but it can hide important details. Two drugs may both have mOS of 18 months, but one may produce a longer survival tail after two years. The median alone may not capture these patterns.

Common investor mistake: treating pooled mOS as treatment-arm mOS

In blinded trials, companies sometimes report pooled survival. Pooled survival combines patients from both the experimental arm and control arm. If a company says pooled mOS has not been reached, that does not mean the experimental drug’s mOS has not been reached. It only means that, across all patients combined, fewer than half have died.

The control arm may be doing better than expected. The experimental arm may be doing better. Both may be doing better. Without unblinding, investors cannot know.

Common investor mistake: assuming higher mOS always means approval

A drug with mOS of 20 months may look impressive. But if the control arm has mOS of 19 months, the treatment effect may be too small. A drug with mOS of 14 months may be meaningful if the control arm has mOS of 8 months.

The important question is not just “how long did patients live?” The important question is: How much longer did patients live versus the control arm, and was the difference statistically and clinically meaningful?

What to check before trusting an mOS headline

Before reacting to an mOS number, ask:

1. Was the trial randomized?
2. Was there a control arm?
3. Was mOS measured from diagnosis, remission, randomization or treatment start?
4. Was the data mature?
5. Was median reached in both arms?
6. How many patients were censored?
7. Was the control arm modern and relevant?
8. Was the result statistically significant?
9. What was the hazard ratio?
10. Did post-progression therapy affect OS?

Frequently asked questions

What does median overall survival (mOS) mean?

Median overall survival is the point in time at which half of the patients in a study group have died and half are still alive. If a trial reports an mOS of 18 months, 50% of patients in that group were alive at 18 months and 50% had died. It is a median, not an average, so it is not the same as mean survival time.

Is mOS the same as average survival?

No. mOS is the median of the survival distribution, meaning the halfway point where 50% of patients have had the event. Average (mean) survival can be pulled up or down by a small number of very long or very short survivors, so it can differ meaningfully from the median. Oncology trials almost always report the median rather than the mean.

Why can a higher mOS still fail to win approval?

Because approval depends on the difference versus the control arm, not the absolute number. A drug with an mOS of 20 months looks strong, but if the control arm reaches 19 months the treatment effect may be too small. A drug with an mOS of 14 months can be meaningful if the control arm only reaches 8 months. What matters is how much longer patients lived versus control, and whether that difference was statistically and clinically significant.

What does mOS not reached mean?

It means fewer than half of the patients in that group have died by the analysis date, so the survival curve has not yet crossed the 50% mark. It can be encouraging, but it can also simply mean the data are immature or follow-up is short. In blinded trials, pooled mOS not being reached does not prove the experimental arm is performing well.

Bottom line

mOS is one of the most important metrics in cancer drug development, but it is often overinterpreted.

mOS matters most when it is arm-level, mature, randomized, statistically significant and clinically meaningful. A single mOS headline is not enough. Always read the trial design.